Surgical Innovations Share Discussion Threads

[bashor] 14/9/2018 09:05

I’m more than top heavy here but happy with the risk/reward, good luck

[jmf69] 14/9/2018 08:49

If I had any spare cash I'd be loading up right now. Already have a good chunk in my SIPP.Gla

[bashor] 14/9/2018 08:33

Just added another 250K I have a good feeling about 2019

[jmf69] 13/9/2018 21:51

https://www.linkedin.com/feed/update/urn:li:activity:6440883900494413824

[bashor] 13/9/2018 16:03

Thanks for the link to the YEP article

[buywell3] 13/9/2018 14:39

Margins above 60% would be good

2019 is the year for SUN to shine says Melanie

Melanie Ross, chief operating officer and chief financial officer, said:

“The predominant headwinds were due to the retraction of CELLIS. We got it back a few weeks ago. Now we need to think about how to relaunch that product.

It will give us a real upswing in 2019. It’s a fantastic product.”

Ms Ross said: “The winter flu crisis is now gone and we are seeing funding coming to fruition.

We are starting to see really strong signs on the NHS.”

Read more at:

[jmf69] 13/9/2018 10:47

The industrial business is high margin as is the Cellis product sales. Both will not only add to the revenue but also help lift margins.

[bashor] 13/9/2018 10:39

Turnover is vanity profit is sanity, I welcome the increase in revenue but they have to control costs to increase margins wherever possible, looking forward to seeing this grow and reward shareholders at last

[jmf69] 13/9/2018 09:38

Industrial orders ramping up and will boost numbers for H2 and going into 2019.

[buywell3] 13/9/2018 08:08

Yes , nice to see some SUN good news

£6M second half now looks very doable giving £11.3M target

However sales of Fix8 by AMS are now uptrending once more in the second quarter , so I would like to see £11.5M hit

IMO for 2019 I think with more certifications due before the year end

£13m is IMO the SUN target with new products coming to market in various countries


13 September 2018



CE mark certification obtained for CELLIS range

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, provides a further update relating to the CELLIS range of products supplied to its UK distribution business, Elemental Healthcare Limited ("Elemental") by Meccellis Biotech SA ("Meccellis").

On 12 September 2018, Elemental received confirmation from Meccellis that CE certification has been issued in respect of the full range of CELLIS products previously sold by Elemental, and also covering innovative new products including the CELLIS Breast Pocket range launched at the London Breast meeting on 6 & 7 September 2018. The certificates are valid until August 2023.

Meccellis are now in a position to resume manufacture of these products, and detailed plans are in progress to facilitate a timely and controlled reintroduction to the UK market in coming weeks.

[jmf69] 13/9/2018 07:09

Confirmation received earlier than I expected. Great news.

[buywell3] 12/9/2018 15:09

Good to see AMS are making progress once again with SUN Fix8 device following design modifications completed by SUN first quarter 2018.

Current AMS latest

''highest level of quarterly sales for this product in Q2 2018 resulting in H1 2018 sales increasing by 16% at reported and constant currency to GBP1.0 million (2017 H1 GBP0.8 million)''

One of the new applications is going to be for gastric sleeve surgery



This will IMO be a big market worldwide as Obesity rates are soaring and this surgery is aimed directly at those with a BMI of 40 and above.

A recent global study reported morbid obesity levels were 23·1% in American women.

Across England, Wales, and Scotland, morbid obesity (BMI of 40kg/m² or over) rates in adults are expected to soar over the next 17 years, with the number of morbidly obese adults likely to exceed 4 million by 2035 -- more than double the 1.9 million in 2015, according to new research being presented at this year's European Congress on Obesity (ECO) in Vienna, Austria (23-26 May).







IMO the addition of gastric sleeve surgery for Fix8 has the potential to increase the use of FiX8 by a factor of at least 3 within 3 years.

''Gastric sleeve surgery

Also known as sleeve gastrectomy, makes the stomach approximately 75 percent smaller. The remaining stomach is a tubular pouch the size and shape of a banana. This limits the amount of food you can eat and makes you feel fuller sooner after eating small amounts of food which leads to reduced calorie intake and ultimately weight loss.

History of the gastric sleeve

Gastric sleeve surgery is one of the newest types of weight loss surgery to treat severe obesity. Historically, it was used as the first step in a two staged obesity treatment. It was found that some patients lost enough weight with a sleeve gastrectomy alone and that the second stage of the operation was not required.

The emergence of the gastric sleeve as a primary procedure has resulted in a shift in the world of bariatric surgery.''



I expect at least one more application of Fix8 to be announced within the next 12 months

[jmf69] 12/9/2018 08:08

From ams results...LiquiBand(R) Fix8(TM)The design modifications for LiquiBand(R) Fix8(TM), our hernia mesh fixation device were completed in the first quarter of 2018, and the new version is now being fully promoted. Surgeon feedback has been extremely positive, and we recorded our highest level of quarterly sales for this product in Q2 2018 resulting in H1 2018 sales increasing by 16% at reported and constant currency to GBP1.0 million (2017 H1 GBP0.8 million). Clinical work is ongoing to broaden the claims to include other laparoscopic surgical applications, such as gastric sleeve surgery.At present, the laparoscopic device is approved for use in Europe and those markets that accept European approval standards. We have begun the US approval process which is expected to take another two years and to cost approximately GBP3 million as it will necessitate a full set of clinical trials. These are expected to start early next year, once we obtain the Investigational Device Exemption with the FDA.Development of the open surgery hernia mesh fixation device is close to completion and EU approval for this product is expected this year.We continue to be excited for the long term prospects for LiquiBand(R) Fix8(TM).

[bashor] 11/9/2018 16:45

Gbh2, I’ll try be a first making a good profit then, well good in my eyes don’t have as much in the markets these days but still sizeable with this one

[gbh2] 11/9/2018 15:53

1998 Bashor, sold the lot May 2011 for a good profit most of which was neutralised when it was found the former Boardroom crew had been spinning a yarn as to how well they were doing.

I watch them these days and I do have a few but I don't believe many PIs have ever made much out of this company, certainly nothing like what the old crew and the new crew make annually in Pay & Shares.

[bashor] 11/9/2018 15:25

Now that depends when you made your investment gbh2 and also the timing of your sells, I’d like to see them making some bigger personal investments then when free cash allows next year the start of a buyback

[xylemflow] 11/9/2018 15:21

I wonder why you would say this in relation to Surgical Innovations?

[gbh2] 11/9/2018 13:49

As with most UK investments the Company Directors are the only one making a profit atm!

[bashor] 11/9/2018 12:54

It wasn’t a bad year for SUN this year, hopefully it’ll be a mild winter without any storms

[buywell3] 11/9/2018 12:33

2019 looks like being a good year for SUN

[romeike] 11/9/2018 10:39

Today is a top up day!

[lurki0] 11/9/2018 09:34

Whereas earlier I think we had only an 'indication' of re-certification, now we have actual confirmation:

"All current products, together with an innovative new range, were re-certified in August and will come back on-stream in the last quarter of the year." Good.

A measured statement with a clear,informative update. Since the company is now free of debt incurred by the Elemental acquisition there should be a lot more cash making its way to the bottom line. Results in six months' time should start showing this to vivid effect.

Short term, of course, the share price will plod a bit while those who recently bought in on the expectation of a post-results spike up leave the building. Which is fine. At this level I will continue to dip in.

[bashor] 11/9/2018 09:20

Agreed let’s get the short term holders looking for a quick buck out, steady away in H2 with further growth and debt free, what’s not to like

[cumnor] 11/9/2018 09:18

Happy enough with that-potential here and seems to be tightly run. Lets hope they deliver now on sales growth. share price will start to rise once impatient post results sellers have been sorted by the mms.

[bashor] 11/9/2018 09:13

Looks solid enough to me, I’ll remain a holder